Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medco Reaches Risk-Sharing Rebate Agreements For 75% Of Part D Spend

This article was originally published in The Pink Sheet Daily

Executive Summary

The PBM is "very comfortable" that its rebating model is not outside of legal safe harbors, CEO Snow says. Under such formulary agreements, Medco receives incremental rebates when utilization exceeds set levels within a therapeutic category.

You may also be interested in...



Medicare Part D Market Is About More Than Just Price, Express Scripts Says

CEO Paz says employers are increasingly interested in alternative solutions to lower drug costs, such as mandatory generics and mandatory mail-order programs. While not the only consideration in choosing a drug plan, price will remain important to clients, the exec says.

Medicare Part D Market Is About More Than Just Price, Express Scripts Says

CEO Paz says employers are increasingly interested in alternative solutions to lower drug costs, such as mandatory generics and mandatory mail-order programs. While not the only consideration in choosing a drug plan, price will remain important to clients, the exec says.

Service Fees, Lower Brand Discounts Replacing Rebate Revenue For Medco

Medco is passing on an increasingly higher percentage of rebates to clients, CFO JoAnn Reed said during a quarterly earnings call April 26

Related Content

Topics

UsernamePublicRestriction

Register

PS062079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel